Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Phase II Reactions: Glucuronidation01:24

Phase II Reactions: Glucuronidation

Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structured Exercise Program After Adjuvant Chemotherapy for Colon Cancer: A Cost-Utility Analysis of the CHALLENGE Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Clinical and molecular correlates of circulating tumor fraction in patients with metastatic pancreatic ductal adenocarcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma.

Nature communications·2026
Same author

A Tobit Partly Linear Mixed and Mixture Cure Model for the Joint Analysis of Interval-Bounded Longitudinal Measurements and Survival Times With Cure Proportion.

Pharmaceutical statistics·2026
Same author

Effects of a structured exercise program on motivational outcomes in patients with colon cancer.

Journal of the National Cancer Institute·2026
Same author

The Late Quaternary climate impact on the genome of the woodland strawberry (Fragaria vesca), a perennial herb.

Communications biology·2026

Related Experiment Video

Updated: Jun 25, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Alternate endpoints for screening phase II studies.

Neesha Dhani1, Dongsheng Tu, Daniel J Sargent

  • 1Princess Margaret Hospital, Toronto, Ontario, Canada.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|March 12, 2009
PubMed
Summary

Phase II trials traditionally use response rates (RR) to assess drug efficacy. Novel endpoints are needed as some targeted agents show benefit despite low RRs, preventing premature drug development termination.

Related Experiment Videos

Last Updated: Jun 25, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Area of Science:

  • Clinical trial design and methodology
  • Oncology drug development

Background:

  • Phase II trials are critical for identifying effective cancer agents and halting development of ineffective ones.
  • Traditional endpoints like response rates (RR) may not capture the full benefit of novel targeted therapies.
  • Recent observations show survival benefits with molecularly targeted agents despite modest RRs, creating a development dilemma.

Purpose of the Study:

  • To review the current status of phase II trial endpoints in oncology.
  • To discuss the challenges posed by novel targeted agents with low response rates.
  • To explore and evaluate alternative or complementary endpoints for phase II trials.

Main Methods:

  • Review of existing literature on phase II trial endpoints.
  • Retrospective analysis of two international gastrointestinal cancer studies.
  • Exploration of novel endpoints including multinomial outcomes, progression-free survival, biomarkers, and continuous tumor size evaluation.

Main Results:

  • Traditional response rates (RR) may be insufficient for evaluating certain novel targeted agents.
  • Alternative endpoints show potential utility in assessing drug activity in early-phase trials.
  • Retrospective analyses suggest promise for novel endpoint approaches in gastrointestinal cancer studies.

Conclusions:

  • The utility of traditional response rates (RR) as a surrogate endpoint in phase II trials is being challenged by novel targeted therapies.
  • Alternative endpoints require further evaluation and prospective validation before adoption as primary phase II endpoints.
  • Careful consideration of endpoints is crucial to balance the risks of terminating promising agents and advancing ineffective ones.